Medical Inventi, a Polish biotech company, has obtained a subsidy from European Funds, My company Polska reports. The funds will aid the research and implementation of the production of its innovative biomaterial allowing for regeneration of cartilage and bone defects — FlexiOss.
- Medical Inventi is a biotechnology company founded in 2015 as an initiative of the academic community of the Medical University of Lublin and private capital. The company aims to commercialize scientific research implemented for the purposes of prevention and protection of human health.
- FlexiOss is two-phase biomaterial used in the regeneration of cartilage and bone defects on the veterinary market. The FlexiOss project will consist of R&D work and the production implementation afterwards.
“We are happy that our projects are getting noticed. This is also the case where we received funding from European Funds for research and product implementation in the amount of nearly one million zlotys. The result of this implementation will be a new, innovative product under the working name OsteoChondral Graft,”
Maciej Maniecki, president of the management board of Medical Inventi, comments.
- The amount of contribution from European Funds is €223,000 (PLN 963,000), and the value of the entire project is over €350,000 (PLN 1.5 million).
- The project will be the starting point for subsequent projects, the final goal of which is the certification of the product as a medical device opted for human care and its commercialization.
